Table 5.
Predictor of overall survival | n (%) | Univariate analysis |
Multivariate analysisa |
||
---|---|---|---|---|---|
HR (95% CI) | P-value | HR (95% CI) | P-value | ||
AFP ≥200 ng/ml versus AFP <200 ng/ml | 60 (17%) | 2.56 (1.46–4.48) | 0.001 | 2.4 (1.3–4.2) | 0.003 |
Preoperative transarterial chemoembolization | 25 (7%) | 2.20 (0.94–5.19) | 0.07 | ||
Major hepatectomy | 38 (11%) | 1.01 (0.46–2.23) | 0.98 | ||
Pedicle clamping | 85 (24%) | 0.95 (0.58–1.56) | 0.84 | ||
Blood transfusion requirement | 28 (8%) | 1.68 (0.72–3.88) | 0.23 | ||
Cirrhosis | 247 (70%) | 3.2 (1.6–6.7) | 0.002 | 2.9 (1.2–6.7) | 0.02 |
Single versus multiple HCC | 302 (86%) | 3.0 (1.74–5.12) | <0.0001 | ||
Encapsulated HCC | 162 (46%) | 1.26 (0.79–2.01) | 0.33 | ||
Satellite nodules | 81 (23%) | 2.21 (1.36–3.59) | 0.001 | ||
Poor versus good/moderate differentiation | 32 (9%) | 3.0 (1.6–5.5) | 0.0003 | ||
Vascular invasion | 99 (34%) | 2.5 (1.59–4.0) | <0.0001 | 2.65 (1.6–4.4) | 0.0002 |
Tumour-free versus not tumour-free margin | 323 (92%) | 0.64 (0.27–1.49) | 0.3 |
Cox's regression model multivariate analysis included all variables with a P-value of <0.15 in univariate analysis.
HR, hazard ratio; 95% CI, 95% confidence interval; AFP, α-fetoprotein.